US Patent

US11938130 — Stable pharmaceutical composition for oral administration

Formulation · Assigned to Astellas Pharma Inc · Expires 2036-07-01 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable pharmaceutical composition for oral administration of gilteritinib fumarate or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11938130
Jurisdiction
US
Classification
Formulation
Expires
2036-07-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.